Hanmi Pharmaceutical Co., Ltd.
Hanmi Pharmaceutical Co., Ltd. has 2 licensing announcements in this dataset, dated 2026-06-01 to 2026-08-24.
- Country / operating region
- South Korea
- Ticker
- 查無
- Headquarters
- 查無
- Founded
- 查無
- Business
- Pharmaceutical research and development
- Website
- www.hanmipharm.com
Pipeline / products
| Asset / platform | Target | Modality | Stage at announcement | Announcement date |
|---|---|---|---|---|
| LAPS GLP-2 analog | GLP-2 receptor | peptide | phase2 | 2026-06-01 |
| HM17321 | UCN2 pathway | peptide | phase1 | 2026-08-24 |
Licensing deals
| Date | Counterparty | Asset / platform | Upfront | Near-term | Milestones | Potential total | Other disclosed terms |
|---|---|---|---|---|---|---|---|
| 2026-06-01 | Eli Lilly and Company | LAPS GLP-2 analog | USD 75m | 查無 | ≤ USD 1185m | 查無 | — |
| 2026-08-24 | Genentech, Inc. | HM17321 | USD 190m | 查無 | 查無 | ≈ USD 2300m | — |
| Counterparty | Territory | Royalties |
|---|---|---|
| Eli Lilly and Company | Worldwide excluding South Korea | Royalties following product launch; rate not disclosed. |
| Genentech, Inc. | Worldwide excluding South Korea | Tiered royalties on future product sales following commercialization. |
Catalysts
查無
Latest monthly revenue
查無
Most advanced drug
查無